Baylor Scott & White Health

Summary

Baylor Scott & White Health is a medical facility located in Temple, Texas. This center is recognized for care of Leukemia, Breast Cancer, Cancer, Brain Tumor, Glioblastoma and other specialties. Baylor Scott & White Health is involved with conducting 43 clinical trials across 112 conditions. There are 3 research doctors associated with this hospital, such as Beth Scholz, OBI Investigator Site, and Sherronda Henderson, MD.

Top PIs

Clinical Trials running at Baylor Scott & White Health

Glioblastoma

Brain Tumor

Colorectal Cancer

Heart Failure

Brain Cancer

Cancer

Tumors

Respiratory Distress Syndrome

Respiratory Impairment

Infections and Infestations

Niraparib vs Temozolomide

for Brain Cancer

The goal of this Phase 3 clinical trial is to compare the efficacy of niraparib versus temozolomide (TMZ) in adult participants with newly-diagnosed, MGMT unmethylated glioblastoma multiforme (GBM). The main question it aims to answer is: Does niraparib improve overall survival (OS) compared to TMZ? Participants will be randomly assigned to one of two treatment arms: niraparib or TMZ. * study drug (Niraparib) or * comparator drug (Temozolomide - which is the standard approved treatment for MGMT unmethylated glioblastoma). The study medication will be taken daily while receiving standard of care radiation therapy (RT) for 6-7 weeks. Participants may continue to take the niraparib or TMZ adjuvantly as long as the cancer does not get worse or completion of 6 cycles of treatment (TMZ). A total of 450 participants will be enrolled in the study. Participants' tasks will include: * Complete study visits as scheduled * Complete a diary to record study medication

Recruiting

2 awards

Phase 3

3 criteria

Keto Diet vs Standard Cancer Diet

for Glioblastoma

This is a Phase 2, randomized two-armed, multi-site study of 170 patients with newly diagnosed glioblastoma multiforme. Patients will be randomized 1:1 to receive Keto Diet, or Standard Anti-Cancer Diet. All patients will receive standard of care treatment for their glioblastoma. The Keto Diet intervention will be for an 18-week period and conducted by trained research dietitians. Daily ketone and glucose levels will be recorded to monitor Keto Diet adherence. This two-armed randomized multi-site study aims to provide evidence to support the hypothesis that a Keto Diet vs. Standard Anti-Cancer Diet improves overall survival in newly diagnosed glioblastoma multiforme patients who receive standard of care treatment.

Recruiting

0 awards

Phase 2